Three major research investigations in Batten disease continue to seek patients to participate in clinical trials in the U.S. and Europe. Studies led by the Department of Genetic Medicine at Weill Cornell Medical College in New York City, by the University of Rochester Batten Center in Rochester, New York, and by California-based pharmaceutical company BioMarin are now enrolling eligible patients for treatment studies for late infantile CLN2 disease and Juvenile NCL. For details on each study and enrollment criteria, go to: Clinical Trial Updates
